Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Survival of BRCA1 breast and ovarian cancer patients : a population-based study from southern Sweden

  • O T Jóhannsson
  • J Ranstam
  • Åke Borg
  • Håkan Olsson
Publishing year: 1998-02
Language: English
Pages: 397-404
Publication/Series: Journal of Clinical Oncology
Volume: 16
Issue: 2
Document type: Journal article
Publisher: American Society of Clinical Oncology

Abstract english

PURPOSE: Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated.

PATIENTS AND METHODS: The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group.

RESULTS: No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1-associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8).

CONCLUSION: The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.


  • Cancer and Oncology
  • Adult
  • Aged
  • Breast Neoplasms
  • Female
  • Genes, BRCA1
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Ovarian Neoplasms
  • Survival Rate
  • Sweden


  • Lund Melanoma Study Group
  • ISSN: 0732-183X
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2